Lilly and Sanofi Settle Insulin Glargine Dispute

Eli Lilly has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine product, Basaglar.

As a part of the agreement, Lilly and its alliance partner, Boehringer Ingelheim, can launch Basaglar in the U.S. on December 15, 2016. Sanofi has granted Lilly a royalty-bearing license so Lilly can manufacture and sell Basaglar in the Kwikpen device globally.

FDA tentatively approved Basaglar in August 2014. With this resolution, Lilly plans to request final approval of Basaglar from the FDA.

"The settlement agreement ends the legal dispute between Lilly and Sanofi and provides us with certainty as it relates to our U.S. launch timing," said Michael J. Harrington, senior vice president and general counsel for Lilly.